1. HbA1c differences between intensively and conventionally treated patients in major clinical trials, with baseline to endpoint HbA1c level in type 1 diabetes (DCCT, SDIS) and type 2 diabetes (UKPDS, Kumamoto).
HbA1c differences between intensively and conventionally treated patients in major clinical trials, with baseline to endpoint HbA1c level in type 1 diabetes (DCCT, SDIS) and type 2 diabetes (UKPDS, Kumamoto).
Mohammad Saleh, and George Grunberger Clin Diabetes 2001;19:
©2001 by American Diabetes Association